References
- Brady HR. Fibrillary glomerulopathy. Kidney Int. 1998 May; 53(5):1421-1429.
- Nasr SH, Vrana JA, Dasari S, et al. DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis. Kidney Int Rep. 2017 Aug 8;3(1):56-64.
- Nachman H.P, Jennette J.C, Falk J.R. Primary Glomerular Diseases. In: Brenner and Rector’s The Kidney, 8th ed.W B Saunders Co. 2007. pp 1032-1034.
- DynaMed. Glomerular Diseases Due to Nonamyloid Organized Deposits. EBSCO Information Services. Accessed September 11, 2022. www.dynamed.com/condition/glomerular-diseases-due-to-nonamyloid-organized-deposits.
- Yazaki M, Ikeda S. Characterization of amyloidosis. Brain Nerve. 2014 Jul;66(7):723-730.
- Misumi Y, Ando Y. Classification of amyloidosis. Brain Nerve. 2014 Jul;66(7):731-737.
- Rosenstock JL, Markowitz GS, Valeri AM, et al. Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features. Kidney Int. 2003 Apr;63(4):1450-1461.
- Korbet SM, Schwartz MM, Lewis EJ. Immuotactoid Glomerulopathy (Fibrillary Glomerulonephritis). CJASN. 2006;1(6):1351-1356.
- Korbet SM, Schwartz MM, Lewis EJ. Immunotactoid glomerulopathy. Am J Kidney Dis. 1991 Mar;17(3):247-257.
- Schwartz MM. Immunotactoid glomerulopathy: The case for Occam’s razor. Am J Kidney Dis. 1993(22):446-447.
- Alpers SM. Fibrillary glomerulonephritis and immunotacotoid glomerulopathy: Two entities, not one. Am J Kidney Dis. 1993(22): 448-451.
- Pronovost PH, Brady HR, Gunning ME, et al. Clinical features, predictors of disease progression and results of renal transplantation in fibrillary/immunotactoid glomerulopathy. Nephrol Dial Transplant. 1996 May;11(5):837-842.
- Kyle R.A, Bayrd E.D. Amyloidosis: review of 236 cases. Medicine (Baltimore). 1983.54:271-299.
- Gertz MA, Kyle RA. Amyloidosis: prognosis and treatment. Semin Arthritis Rheum. 1994 Oct;24 (2):124-138.
- Kyle RA, Wagoner RD, Holley KE. Primary systemic amyloidosis: Resolution of the nephrotic syndrome with melphalan and prednisone. Arch Intern Med. 1982(142):1445-1447.
- Sanchorawala V, Wright DG, Seldin DC, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant. 2001 Oct;28(7):637-642.
- Leung N, Dispenzieri A, Fervenza FC, et al. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis. Am J Kidney Dis. 2005 Aug;46(2):270-277.
- Sidana S, Sidiqi MH, Dispenzieri A, et al. Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. Am J Hematol. 2019 Sep;94(9):1020-1026.
- Joss N, McLaughlin K, Simpson K, et al. Presentation, survival and prognostic markers in AA amyloidosis, QJM: An International Journal of Medicine, 2000 Aug:93(8):535–542.
- Bergesio F, Ciciani AM, Santostefano M, et al. Immunopathology Group, Italian Society of Nephrology. Renal involvement in systemic amyloidosis--an Italian retrospective study on epidemiological and clinical data at diagnosis. Nephrol Dial Transplant. 2007 Jun;22(6):1608-1618.
- Hogan J, Restivo M, Canetta PA, et al. Rituximab treatment for fibrillary glomerulonephritis. Nephrol Dial Transplant. 2014 Oct;29(10):1925-1931.
- Nasr SH, Kudose SS, Said SM, et al. Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants. Kidney Int. 2021 Feb;99(2):410-420